Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lantheus (LNTH – Research Report), Innate Pharma (IPHA – Research Report) and Olink Holding (OLK – Research Report) with bullish sentiments.

Lantheus (LNTH)

SVB Securities analyst Roanna Ruiz maintained a Buy rating on Lantheus today and set a price target of $120.00. The company’s shares closed last Monday at $57.25.

According to TipRanks.com, Ruiz has 0 stars on 0-5 stars ranking scale with an average return of -43.7% and a 12.0% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.

Currently, the analyst consensus on Lantheus is a Strong Buy with an average price target of $107.75, a 91.6% upside from current levels. In a report issued on November 4, JonesTrading also maintained a Buy rating on the stock with a $104.00 price target.

See today’s best-performing stocks on TipRanks >>

Innate Pharma (IPHA)

SVB Securities analyst Daina Graybosch maintained a Buy rating on Innate Pharma today and set a price target of $9.00. The company’s shares closed last Monday at $2.48, close to its 52-week low of $1.92.

According to TipRanks.com, Graybosch has 0 stars on 0-5 stars ranking scale with an average return of -17.4% and a 32.4% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Molecular Partners, and LAVA Therapeutics.

Innate Pharma has an analyst consensus of Strong Buy, with a price target consensus of $10.83.

Olink Holding (OLK)

In a report released today, Puneet Souda from SVB Securities maintained a Buy rating on Olink Holding, with a price target of $27.00. The company’s shares closed last Monday at $20.68.

According to TipRanks.com, Souda is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.4% and a 41.4% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

Currently, the analyst consensus on Olink Holding is a Moderate Buy with an average price target of $22.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LNTH:

• Analysts Offer Insights on Financial Companies: Two Harbors (TWO) and Modiv (MDV)
• Monarch Announces Debt Settlement
• Gorilla Technology Group Inc. Appoints Industry Veteran Max Lin as General Manager, Taiwan
• Sigyn Therapeutics Announces Third Quarter 2022 Financial Results
• Patriot One Technologies Selected to Secure All Entrances at OVG360’s New Acrisure Arena